SiNtx Technologies SINT 深 沪
等待开盘 05-21 09:30:00 美东时间
2.21
+0.010
+0.45%
华盛通- 最 高2.24
- 今 开2.222
- 成交量 2.25万股
- 最 低 2.17
- 昨 收 2.20
- 总市值 910.90万
- 52周最高 6.78
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 1.99
- 委 比 98.02%
- 总股本 412.17万
- 历史最高 209400.00
- 量 比 0.90
- 振 幅 3.18%
- 历史最低 1.71
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
今天 12:05
HC Wainwright & Co. Reiterates Buy on SINTX Technologies, Maintains $10 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates SINTX Technologies (NASDAQ:SINT) with a Buy and maintains $10 price target.
05-20 18:48
SINTX Technologies Q1 EPS $(0.70) Misses $(0.66) Estimate, Sales $380.000K Beat $300.000K Estimate
SINTX Technologies (NASDAQ:SINT) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.66) by 6.06 percent. This is a 45.74 percent increase over losses of $(1.29) per share
05-16 06:54
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
Ascendiant Capital Maintains Buy on SINTX Technologies, Lowers Price Target to $12
Ascendiant Capital analyst Edward Woo maintains SINTX Technologies (NASDAQ:SINT) with a Buy and lowers the price target from $16 to $12.
04-08 17:55
BUZZ-SINTX rises after first use of FDA-cleared implant, names new president
BUZZ-SINTX rises after first use of FDA-cleared implant, names new president ** Shares of biomaterials maker SINTX Technologies SINT.O rise 7% to $2.75 ** Co says a surgeon performed the first human surgery using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, marking SINTX's entry int
03-23 21:59
快讯 | SINTX Technologies提供了企业业务更新，重点介绍了首次人体植入、战略转型和商业执行情况。
SINTX Technologies Provides Corporate Business Update Highlighting First Human ...
03-23 21:15
SINTX Technologies Completes First-In-Human Surgical Procedure Utilizing FDA-Cleared SINAPTIC Foot & Ankle Osteotomy Wedge System
Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platformSALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE)
03-19 19:39
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
SiNtx Technologies successfully completed the first-in-human surgical procedure using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone. This entry into the foot and ankle reconstruction market advances the commercialization of its silicon nitride biomaterial platform. The system, cleared in October 2025, integrates surgeon-informed design with silicon nitride technology, showcasing os...
03-19 11:30
